LIFECORE BIOMEDICAL, INC. Payments to Acquire Marketable Securities
LIFECORE BIOMEDICAL, INC. (LFCR) reported Payments to Acquire Marketable Securities of $1.42 million for the 12-month period ending 2014-05-25, per its 10-K filed 2016-08-01.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2016-08-01
- LIFECORE BIOMEDICAL, INC. payments to acquire marketable securities for the quarter ending 2014-05-25 was $0.00.
- LIFECORE BIOMEDICAL, INC. payments to acquire marketable securities for the quarter ending 2014-02-23 was $0.00, a 100.00% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. payments to acquire marketable securities for the quarter ending 2013-11-24 was $0.00, a 100.00% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. payments to acquire marketable securities for the quarter ending 2013-08-25 was $1.42M, a 87.43% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. payments to acquire marketable securities for fiscal 2014 was $1.42M, a 71.43% decline from fiscal 2013.
- LIFECORE BIOMEDICAL, INC. payments to acquire marketable securities for fiscal 2013 was $4.96M, a 83.86% decline from fiscal 2012.
- LIFECORE BIOMEDICAL, INC. payments to acquire marketable securities for fiscal 2012 was $30.72M, a 48.65% decline from fiscal 2011.
- LIFECORE BIOMEDICAL, INC. payments to acquire marketable securities for fiscal 2011 was $59.83M, a 11.27% decline from fiscal 2010.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2014-05-25 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-01 | $0.00 derived: sum of 2 quarters · filed 2016-08-01 | $0.00 derived: sum of 3 quarters · filed 2016-08-01 | $1.42M 10-K · filed 2016-08-01 |
| 2014-02-23 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-04-02 | $0.00 derived: sum of 2 quarters · filed 2015-04-02 | $1.42M 10-Q · filed 2015-04-02 | $1.14M derived: sum of 4 quarters · filed 2015-07-31 |
| 2013-11-24 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-01-09 | $1.42M 10-Q · filed 2015-01-09 | $1.14M derived: sum of 3 quarters · filed 2015-07-31 | $3.92M derived: sum of 4 quarters · filed 2015-07-31 |
| 2013-08-25 | $1.42M 10-Q · filed 2014-10-08 | $1.14M derived: sum of 2 quarters · filed 2015-07-31 | $3.92M derived: sum of 3 quarters · filed 2015-07-31 | $5.62M derived: sum of 4 quarters · filed 2015-07-31 |
| 2013-05-26 | -$280.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-07-31 | $2.50M derived: sum of 2 quarters · filed 2015-07-31 | $4.20M derived: sum of 3 quarters · filed 2015-07-31 | $4.96M 10-K · filed 2015-07-31 |
| 2013-02-24 | $2.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-03-28 | $4.48M derived: sum of 2 quarters · filed 2014-03-28 | $5.24M 10-Q · filed 2014-03-28 | $10.28M derived: sum of 4 quarters · filed 2014-08-01 |
| 2012-11-25 | $1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-01-03 | $2.46M 10-Q · filed 2014-01-03 | $7.50M derived: sum of 3 quarters · filed 2014-08-01 | $14.12M derived: sum of 4 quarters · filed 2014-08-01 |
| 2012-08-26 | $756.00K 10-Q · filed 2013-09-26 | $5.80M derived: sum of 2 quarters · filed 2014-08-01 | $12.41M derived: sum of 3 quarters · filed 2014-08-01 | $13.32M derived: sum of 4 quarters · filed 2014-08-01 |
| 2012-05-27 | $5.04M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-01 | $11.66M derived: sum of 2 quarters · filed 2014-08-01 | $12.56M derived: sum of 3 quarters · filed 2014-08-01 | $30.72M 10-K · filed 2014-08-01 |
| 2012-02-26 | $6.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-04-04 | $7.52M derived: sum of 2 quarters · filed 2013-04-04 | $25.68M 10-Q · filed 2013-04-04 | $27.91M derived: sum of 4 quarters · filed 2013-08-07 |
| 2011-11-27 | $903.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2013-01-04 | $19.07M 10-Q · filed 2013-01-04 | $21.30M derived: sum of 3 quarters · filed 2013-08-07 | |
| 2011-08-28 | $18.16M 10-Q/A · filed 2013-01-02 | $20.39M derived: sum of 2 quarters · filed 2013-08-07 | ||
| 2011-05-29 | $2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2013-08-07 | $59.83M 10-K · filed 2013-08-07 | ||
| 2011-02-27 | $57.60M 10-Q · filed 2012-03-28 | |||
| 2010-11-28 | $41.78M 10-Q · filed 2012-01-05 | |||
| 2010-08-29 | $34.85M 10-Q · filed 2011-10-05 | |||
| 2010-05-30 | $67.43M 10-K · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |